For example, there is evidence that anti-CTLA-4 and anti-PD-1 therapy results in the upregulation of VISTA in patients with localized prostate adenocarcinoma and metastatic melanoma during treatment forming a basis to test such combination therapies (33, 35). The gene discussed is VSIR; the disease is metastatic melanoma.